Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 18/20 | 0.43 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | CALCA | P06881 | 1/20 | 0.40 |
| ▸ | ADM2 | Q7Z4H4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9894749 | 0.89 | CALCRL (0.45) | CALCRLRAMP1CALCAADM2 | |
| SCHEMBL3045032 | 0.88 | CALCRL (0.45) | CALCRLRAMP1CALCAADM2 | |
| SCHEMBL9895135 | 0.84 | CALCRL (0.45) | CALCRLRAMP1CALCAADM2 | |
| SCHEMBL9896154 | 0.84 | CALCRL (0.44) | CALCRLRAMP1CALCAADM2 | |
| SCHEMBL13846566 | 0.83 | CALCRL (0.39) | CALCRLADM2 | |
| SCHEMBL550234 | 0.83 | CALCRL (0.44) | CALCRLRAMP1CALCA | |
| SCHEMBL550430 | 0.83 | CALCRL (0.44) | CALCRLRAMP1CALCA | |
| SCHEMBL3042197 | 0.83 | CALCRL (0.44) | CALCRLRAMP1CALCA | |
| SCHEMBL3049089 | 0.82 | CALCRL (0.46) | CALCRLRAMP1CALCAADM2 | |
| SCHEMBL12923070 | 0.81 | CALCRL (0.45) | CALCRLRAMP1CALCAADM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130245009-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-20130245009-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-20130245009-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-20120149698-A1 | NOUVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
| US-20120149698-A1 | NOUVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
| US-20120149698-A1 | NOUVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149698-A1 | NOUVEL COMPOUNDS | BDKRB2, CALCR, CALCRL | CALCRL 3/4885RAMP1 130/4885HTR2C 798/4885 |
| US-20130245009-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, BDKRB2 | CALCRL 1/4885RAMP1 81/4885HTR2C 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.